Literature DB >> 24955551

Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.

N B Lundin1, M J Niciu1, D A Luckenbaugh1, D F Ionescu1, E M Richards1, J L Vande Voort1, N E Brutsche1, R Machado-Vieira1, C A Zarate1.   

Abstract

INTRODUCTION: Deficiencies in both vitamin B12 and folate have been associated with depression. Recently, higher baseline vitamin B12 levels were observed in individuals with bipolar depression who responded to the antidepressant ketamine at 7 days post-infusion. This study sought to -replicate this result by correlating peripheral vitamin levels with ketamine's antidepressant efficacy in bipolar depression and major depressive disorder (MDD).
METHODS: Baseline vitamin B12 and folate levels were obtained in 49 inpatients with treatment-resistant MDD and 34 inpatients with treatment-resistant bipolar depression currently experiencing a major depressive episode. All subjects received a single intravenous ketamine infusion. Post-hoc Pearson correlations were performed between baseline vitamin B12 and folate levels, as well as antidepressant response assessed by percent change in Hamilton Depression Rating Scale (HDRS) scores from baseline to 230 min, 1 day, and 7 days post-infusion.
RESULTS: No significant correlation was observed between baseline vitamin B12 or folate and percent change in HDRS for any of the 3 time points in either MDD or bipolar depression. DISCUSSION: Ketamine's antidepressant efficacy may occur independently of baseline peripheral vitamin levels. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24955551      PMCID: PMC4174587          DOI: 10.1055/s-0034-1377042

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  22 in total

Review 1.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

2.  Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile.

Authors:  F Martényi; M Dossenbach; K Mraz; S Metcalfe
Journal:  Eur Neuropsychopharmacol       Date:  2001-06       Impact factor: 4.600

3.  Clinical predictors of ketamine response in treatment-resistant major depression.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

4.  Do the dissociative side effects of ketamine mediate its antidepressant effects?

Authors:  David A Luckenbaugh; Mark J Niciu; Dawn F Ionescu; Neal M Nolan; Erica M Richards; Nancy E Brutsche; Sara Guevara; Carlos A Zarate
Journal:  J Affect Disord       Date:  2014-02-18       Impact factor: 4.839

Review 5.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

Review 6.  The definition and meaning of treatment-resistant depression.

Authors:  H A Sackeim
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

7.  Gender differences in treatment response to sertraline versus imipramine in chronic depression.

Authors:  S G Kornstein; A F Schatzberg; M E Thase; K A Yonkers; J P McCullough; G I Keitner; A J Gelenberg; S M Davis; W M Harrison; M B Keller
Journal:  Am J Psychiatry       Date:  2000-09       Impact factor: 18.112

8.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

9.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Authors:  James W Murrough; Dan V Iosifescu; Lee C Chang; Rayan K Al Jurdi; Charles E Green; Andrew M Perez; Syed Iqbal; Sarah Pillemer; Alexandra Foulkes; Asim Shah; Dennis S Charney; Sanjay J Mathew
Journal:  Am J Psychiatry       Date:  2013-10       Impact factor: 18.112

10.  Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression.

Authors:  A Permoda-Osip; J Dorszewska; A Bartkowska-Sniatkowska; M Chlopocka-Wozniak; J K Rybakowski
Journal:  Pharmacopsychiatry       Date:  2013-07-11       Impact factor: 5.788

View more
  5 in total

Review 1.  Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.

Authors:  Steven J Pennybaker; Mark J Niciu; David A Luckenbaugh; Carlos A Zarate
Journal:  J Affect Disord       Date:  2016-10-26       Impact factor: 4.839

Review 2.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Authors:  Nicolas D Iadarola; Mark J Niciu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy B Lundin; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

3.  Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.

Authors:  Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes
Journal:  Mol Psychiatry       Date:  2022-06-27       Impact factor: 15.992

4.  Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.

Authors:  Annie J Xu; Mark J Niciu; Nancy B Lundin; David A Luckenbaugh; Dawn F Ionescu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy E Brutsche; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Neural Plast       Date:  2015-06-07       Impact factor: 3.599

Review 5.  Homocysteine levels in schizophrenia and affective disorders-focus on cognition.

Authors:  Ahmed A Moustafa; Doaa H Hewedi; Abeer M Eissa; Dorota Frydecka; Błażej Misiak
Journal:  Front Behav Neurosci       Date:  2014-10-06       Impact factor: 3.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.